Uganda Spends Shs1.6 Trillion to Import Drugs
Uganda spends $450m (Shs1.6 trillion) on pharmaceutical imports annually.
This was revealed during the Third United Kingdom East Africa Health Investment Conference in Kampala at the weekend.
The import bill in Uganda’s health sector has been growing despite establishing nine pharmaceutical factories in the last 15 years.
The Uganda health sector is estimated to be worth about $1.028b and receivies enormous support from UK since 2013 channeled through Uganda-UK Health Alliance.
Speaking at the conference, Peter West, the British High Commissioner to Uganda, said the private sector was crucial to the development of Uganda’s health sector, urging the private players to invest in health in order to cut back on the increasingly growing import bill.
“I know the British business delegation are keen to explore investment opportunities and to contribute to the sector’s development,” he said, adding that his government will in the next five years invest about £83m (Shs423b) to support improvements in health outcomes.
Dr Sam Orach, the head of the Uganda Catholic Medical Bureau, urged the private sector to invest in the health sector to supplement government efforts.
“Improving the health sector is not a government job alone. This [investment] will reduce the cost of health services and save the country from a huge import bill,” he said.
The conference, which was organised by the UK Department for International Trade, Ministry of Health, Barclays Bank, Prudential and Cipla Quality Chemicals, also discussed other key areas including health infrastructure, access to equipment, medical products supply and insurance.
Mr Rakesh Jha, the Barclays Bank managing director, said their shared focus to promote Uganda’s the health sector has ensured that the bank commits more than $20m (Shs73.2b).
In 2013, The National Policy on Public-Private Partnership in the health sector was approved with key focus on improving access to equity, efficiency, quality and building a sustainable health care system.
Currently, more than 75 per cent of private-not-for-profit providers belong to religious institutions and the rest are run by non-governmental organisations or foundations.
They include the facility-based providers, which offer preventive and curative care including highly specialised services and the non-facility-based which offer preventive, rehabilitative, and palliative care.
Looking for chemical products? Let suppliers reach out to you!
2026-07-21
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
Trump Plans 25% Tariffs on Autos, Drugs and Semiconductor Chips
-
It is expected that the export volume of domestic paste resin is still difficult to improve greatly
-
Pesticide import and export situation in China in August 2022
-
2022H1: Top 10 Best-Selling Drugs in the World
-
What is the chemistry in everyday life drugs?
-
Cinda Biologics Picks Up 7th Heavyweight Variety Of 25 Innovative Drugs Revealed
-
Lianhua Qingwen's Road to Internationalization is Getting Wider and Wider
-
Import of Poultry Meat and Poultry Products Suspended in Poland, France and Some Parts of the United Kingdom
-
Analysis on Import and Export of Fluorine Chemical Raw Materials
Recommend Reading
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Evonik to Spin Off Infrastructure Operations into New Services Company SYNEQT
-
Premium Global Chemical Sourcing Requests (19 - 22 Mar, 2026)
-
Supply Maintains Contraction, Boosting PTA Prices in China
-
Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance
-
Premium Global Chemical Sourcing Requests (30 Aug- 3 Sep 2025)